We are all in this together

With COVID-19 our thoughts turn to the patients and the global communities affected by this epidemic and the healthcare professionals on the front line.

Eisbach believes that developing innovative approaches are essential contributions that our industry can make toward addressing the impact of COVID-19. We believe that as an innovative drug discovery startup, it is our duty and responsibility to act.

Eisbach joins worldwide efforts to combat the pandemic.

Acting now

Eisbach is adding an R&D team aiming to identify new drugs targeting two essential and novel molecular targets in SARS-CoV-2. Such medicines would help treat the infected, reduce symptoms and tissue damage, and thus hopefully reduce mortality.

We aim to promote better health of citizens

Targeting unique and novel mechanisms for COVID-19 therapy

We are identifying novel, efficacious small molecules that target disease-relevant functions in the SARS-CoV-2 virus. Using our innovative allosteric  platform, we have developed inhibitors against an essential SARS-CoV-2 enzyme and molecular machine, for which the founding team has pioneering, worldwide expertise. Since these proteins are essential for the replication of the viral SARS-CoV-2 genome and impact the host’s immune system, they represent highly promising drug targets.

Preclinical validation has been successfully completed and showed that our orally bioavailable inhibitors are effective and can be given at high doses with no detectable toxicity, allowing us to now rapidly progress to clinical development. Such SARS-CoV-2 targeted small molecule drugs will help treat the infected, reduce symptoms and help reduce mortality. Eisbach is poised to develop sustainable drugs that can significantly reduce the societal and health burden of COVID- 19 and of related CoVs.

Pioneering expertise

Novel, cell-active small molecule inhibitors

Drug discovery supported by AI